Biotech Values

[DewDiligence]

PFE 1Q22 results—2022 guidance:

Full-year 2022 sales guidance for the COVID vaccine and Paxlovid remain unchanged from the guidance given in February at $32B and $22B, respectively. However, thee guidance was implicitly raised insofar as the strong US dollar has adversely affected the guidance for the COVID vaccine and Paxlovid by $1.0B and $500K, respectively, relative to the guidance given in February.

1Q22 sales—excluding the COVID vaccine and Paxlovid—were +2% YoY.

2022 non-GAP EPS guidance was reduced by $0.10 due to an SEC-mandated in the accounting for in-process R&D (i.e. accounting for acquisitions); the new range is $6.25-6.45.


PR:
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-first-quarter-2022-results

CC slides:
https://s28.q4cdn.com/781576035/files/doc_financials/2022/q1/Q1-2022-Earnings-Charts-FINAL-(1).pdf

Transcript of CC prepared remarks:
https://s28.q4cdn.com/781576035/files/doc_financials/2022/q1/Q1-2022-Earnings-Conference-Call-Prepared-Remarks-FINAL.pdf

2-page infographic:
https://s28.q4cdn.com/781576035/files/doc_financials/2022/q1/Q1-2022-Pfizer-Earnings-Infographic-FINAL.pdf